CinnaGen is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $8.4B combined in 2025.
| Drug | Brand owner | Copy | US LOE | CinnaGen's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Ocrevus Xacrel |
Roche | Biosimilar | 2029 | Phase 3 reported; US plans unclear | ≈$8.4B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not CinnaGen's share of it.